INFO	Title	Rhabdomyosarcoma (RMS) Data Dictionary									
INFO	Name	rms_v2.0									
INFO	Release Notes										
INFO	Parent Data Model	pcdc_v2.0									
INFO	License	Creative Commons Attribution-NonCommercial 4.0 International License (https://creativecommons.org/licenses/by-nc/4.0/)									
INFO	D4CG Data Modeling Wiki	https://docs.pedscommons.org/									
INFO	Disease Consortium Information	https://commons.cri.uchicago.edu/pcdc/									
INFO	Description	The RMS data dictionary is a consensus data schema built by an international group of pediatric rhabdomyosarcoma experts and maintained by Data for the Common Good (D4CG) at the University of Chicago in collaboration with the International Soft Tissue Sarcoma Consortium (INSTRuCT). It is based on the collective requirements of its contributors.									
INFO	Total Variables										
											
RowType	VariableName	DataType	Tier	VariableDescription	VariableEnum	PermissibleValue	ValueDescription	ValueEnum	ImplementationNotes	Mappings	Modeling Notes (ignored in processing)
											
DD	Protocol										
TD	Subject Characteristics										
TG	One row per subject per study										
VD	HONEST_BROKER_SUBJECT_ID	String		Subject identifier assigned by the honest broker.		_undefined_	_undefined_	_undefined_			
VD	CONSORTIUM	Enum	To-do	The consortium under which this data is being contributed to the Pediatric Cancer Data Commons.	ncit:C61538	_undefined_	_undefined_	_undefined_		New VD	
PD						INSTRuCT	International Pediatric Acute Myeloid Leukemia Consortium (INTERACT). A consortium launched in 2021 as a collaboration between acute myeloid leukemia researchers from Children's Oncology Group, European Pediatric Acute Leukemia, Japan Children's Cancer Group, and St. Jude Children's Research Hospital. To date, INTERACT has identified 18 studies from 10 clinical trials research groups that can be contributed to the data commons, and its statisticians are actively working to harmonize clinical data from more than 6,000 individuals who have had pediatric cancer.	ncit:C192762		New PD	
VD	DISEASE_GROUP	Enum				_undefined_	_undefined_	_undefined_		New VD	
PD						RMS				New PD	
VD	DATA_CONTRIBUTOR_ID	Enum		An identifier assigned to a data contributor.		_undefined_	_undefined_	_undefined_			
PD						COG	Children's Oncology Group. An NCI-supported clinical cooperative group formed by the merger of the four national pediatric cancer research organizations: the Children's Cancer Group, the Intergroup Rhabdomyosarcoma Study Group, the National Wilms Tumor Study Group, and the Pediatric Oncology Group. The primary objective of the organization is to conduct clinical trials of new therapies for childhood and adolescent cancer. COG develops and coordinates clinical trials conducted at the 238 member institutions that include cancer centers of all major universities and teaching hospitals throughout the U.S. and Canada, as well as sites in Europe and Australia. COG members include over 5000 cancer researchers.	ncit:C39353		New PD	
PD						EpSSG	European Paediatric Soft Tissue Sarcoma Study Group. An international organization of healthcare professionals devoted to the care and treatment of children and young people with soft tissue sarcoma.	ncit:C192774		New PD	
PD						CWS	Cooperative Weichteilsarkom Studiengruppe. An international pediatric soft tissue sarcoma study group, also known as the Cooperative Soft Tissue Sarcoma Group, that creates guidance for risk-adapted treatment of soft tissue sarcoma and soft tissue tumors in children, adolescents, and young adults in Europe.	ncit:C192777		New PD	
PD						MMT	International Society of Paediatric Oncology Malignant Mesenchymal Tumour Committee. An international pediatric oncology committee that specializes in the research of malignant mesenchymal tumors. Along with the Associazione Italiana Ematologia Oncologia Pediatrica-Soft Tissue Sarcoma Committee (AIEOP-STSC), which was formerly known as the Italian Cooperative Group (ICG), SIOP-MMT founded the European pediatric Soft tissue sarcoma Study Group (EpSSG) and the Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) study in 2005 with the goal of making pediatric non-rhabdomyosarcoma soft tissue sarcoma treatment uniform across Europe.	ncit:C192775		New PD	
PD						STSC	AIEOP Soft Tissue Sarcoma Committee			New PD	
VD	STUDY_ID	Enum		A sequence of characters used to identify, name, or characterize the study.		_undefined_	_undefined_	_undefined_			
PD						ARST0331	Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma. This non-randomized phase III trial is studying how well combination chemotherapy and radiation therapy work in treating patients with newly diagnosed low-risk rhabdomyosarcoma. (ClinicalTrials.gov Identifier: NCT00075582)			New PD	
PD						ARST0431	Intensive Multi-Agent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide (IE) and Vincristine/Doxorubicin/Cyclophosphamide (VDC) for Patients With High-Risk Rhabdomyosarcoma. This phase III trial is studying how well giving high-dose combination chemotherapy together with radiation therapy works in treating patients with newly diagnosed metastatic rhabdomyosarcoma or ectomesenchymoma. (ClinicalTrials.gov Identifier: NCT00354744)			New PD	
PD						ARST0531	Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) Versus VAC Alternating With Vincristine and Irinotecan (VI) for Patients With Intermediate-Risk Rhabdomyosarcoma (RMS). This randomized phase III trial is studying two different combination chemotherapy regimens to compare how well they work when given together with radiation therapy in treating patients with newly diagnosed rhabdomyosarcoma. (ClinicalTrials.gov Identifier: NCT00354835)			New PD	
PD						ARST08P1	A Pilot Study to Evaluate Novel Agents (Temozolomide and Cixutumumab [IMC-A12, Anti-IGF-IR Monoclonal Antibody NSC # 742460]) in Combination With Intensive Multi-agent Interval Compressed Therapy for Patients With High-Risk Rhabdomyosarcoma. This randomized pilot clinical trial is studying the side effects and how well giving temozolomide and cixutumumab together with combination chemotherapy works in treating patients with metastatic rhabdomyosarcoma. (ClinicalTrials.gov Identifier: NCT01055314)			New PD	
PD						D9602	Results of the Intergroup Rhabdomyosarcoma Study Group D9602 Protocol, Using Vincristine and Dactinomycin With or Without Cyclophosphamide and Radiation Therapy, for Newly Diagnosed Patients With Low-Risk Embryonal Rhabdomyosarcoma: A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group. The objective of this study is to decrease toxicity in similar patients by reducing radiotherapy (RT) doses and eliminating cyclophosphamide for the lowest-risk patients. (Raney RB, Walterhouse DO, Meza JL, et al. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol. 2011;29(10):1312-1318. doi:10.1200/JCO.2010.30.4469)			New PD	
PD						D9802	Rhabdomyosarcoma: Review of the Children’s Oncology Group (COG) Soft-Tissue Sarcoma Committee Experience and Rationale for Current COG Studies. (Malempati S, Hawkins DS. Rhabdomyosarcoma: review of the Children's Oncology Group (COG) Soft-Tissue Sarcoma Committee experience and rationale for current COG studies. Pediatr Blood Cancer. 2012;59(1):5-10. doi:10.1002/pbc.24118)			New PD	
PD						D9803	Vincristine, Actinomycin, and Cyclophosphamide Compared With Vincristine, Actinomycin, and Cyclophosphamide Alternating With Vincristine, Topotecan, and Cyclophosphamide for Intermediate-Risk Rhabdomyosarcoma: Children's Oncology Group Study D9803. The purpose of this randomized study was to compare the outcome of patients with intermediate-risk rhabdomyosarcoma (RMS) treated with standard VAC (vincristine, dactinomycin, and cyclophosphamide) chemotherapy to that of patients treated with VAC alternating with vincristine, topotecan, and cyclophosphamide (VAC/VTC). (DOI: 10.1200/JCO.2009.22.3768 Journal of Clinical Oncology 27, no. 31 (November 01, 2009) 5182-5188.)			New PD	
PD						RMS2005	A Protocol For Nonmetastatic Rhabdomyosarcoma [RMS-2005]. This randomized phase III trial is studying different combination chemotherapy regimens to compare how well they work in treating young patients with nonmetastatic rhabdomyosarcoma. (ClinicalTrials.gov Identifier: NCT00379457)			New PD	
PD						MTS2008	Metastatic Rhabdomyosarcoma: Results of the European Paediatric Soft Tissue Sarcoma Study Group MTS 2008 Study and Pooled Analysis With the Concurrent BERNIE Study. This study presents the results of the MTS 2008 study with a pooled analysis including patients from the concurrent BERNIE study. (Schoot RA, Chisholm JC, Casanova M, et al. Metastatic Rhabdomyosarcoma: Results of the European Paediatric Soft Tissue Sarcoma Study Group MTS 2008 Study and Pooled Analysis With the Concurrent BERNIE Study. J Clin Oncol. 2022;40(32):3730-3740. doi:10.1200/JCO.21.02981)			New PD	
PD						ICG RMS96	Localized vaginal/uterine rhabdomyosarcoma—results of a pooled analysis from four international cooperative groups. The purpose of this study is to explore the impact of radiation therapy on local failure rate and OS when used as part of primary treatment, and to assess the use of intracavitary brachytherapy between the different cooperative groups. (Minard-Colin V, Walterhouse D, Bisogno G, et al. Localized vaginal/uterine rhabdomyosarcoma-results of a pooled analysis from four international cooperative groups. Pediatr Blood Cancer. 2018;65(9):e27096. doi:10.1002/pbc.27096)			New PD	
PD						RMS 4.99	Sequential high-dose chemotherapy for children with metastatic rhabdomyosarcoma. The RMS4.99 study was designed to explore the role of multiple sequential high-dose chemotherapy cycles administered early in the treatment of children with metastatic rhabdomyosarcoma. (Bisogno, Gianni & Ferrari, Andrea & Prete, Arcangelo & Messina, Chiara & Basso, Eleonora & Cecchetto, Giovanni & Indolfi, Paolo & Scarzello, Giovanni & D'Angelo, Paolo & De Sio, Luigi & Di Cataldo, Andrea & Carli, Modesto. (2009). Sequential high-dose chemotherapy for children with metastatic rhabdomyosarcoma. European journal of cancer (Oxford, England : 1990). 45. 3035-41. 10.1016/j.ejca.2009.08.019)			New PD	
PD						CWS-IV-2002	Pediatric Patients with Stage IV Rhabdomyosarcoma Significantly Benefit from Long-Term Maintenance Therapy: Results of the CWS-IV 2002 and the CWS DOK IV 2004-Trials. Report prognostic factors and outcome of patients receiving multimodal treatment for RMS followed by either LTMT, HDCT, or alloHSCT. In addition, we compared the prognosis of patients who received either O-TIE or CYC/VBL as LTMT. The treatment decisions are based on the choice of the treating attending physicians. (Tramsen L, Bochennek K, Sparber-Sauer M, et al. Pediatric Patients with Stage IV Rhabdomyosarcoma Significantly Benefit from Long-Term Maintenance Therapy: Results of the CWS-IV 2002 and the CWS DOK IV 2004-Trials. Cancers (Basel). 2023;15(7):2050. Published 2023 Mar 30. doi:10.3390/cancers15072050)			New PD	
PD						CWS2002P	Long-Term Clinical Outcome and Prognostic Factors of Children and Adolescents with Localized Rhabdomyosarcoma Treated on the CWS-2002P Protocol.  This trial reports the results of the prospective, non-randomized, historically controlled CWS-2002P study in patients ≤ 21 years with localized RMS developed with the aim to improve the long-term outcome by adapting the burden of therapy to risk profile and to investigate the feasibility and relation to the outcome of maintenance therapy (MT) in the high-risk groups. (Koscielniak E, Blank B, Vokuhl C, et al. Long-Term Clinical Outcome and Prognostic Factors of Children and Adolescents with Localized Rhabdomyosarcoma Treated on the CWS-2002P Protocol. Cancers (Basel). 2022;14(4):899. Published 2022 Feb 11. doi:10.3390/cancers14040899)			New PD	
PD						CWS91	Cooperative trial CWS-91 for localized soft tissue sarcoma in children, adolescents, and young adults. The purpose of this trial is to improve risk-adapted therapy for localized childhood soft tissue sarcoma within an international multicenter setting. (Dantonello TM, Int-Veen C, Harms D, et al. Cooperative trial CWS-91 for localized soft tissue sarcoma in children, adolescents, and young adults. J Clin Oncol. 2009;27(9):1446-1455. doi:10.1200/JCO.2007.15.0466)			New PD	
PD						CWS96	Treatment of children with metastatic soft tissue sarcoma with oral maintenance compared to high dose chemotherapy: report of the HD CWS-96 trial. This trial studies the efficacy of high dose therapy (HDT) versus an oral maintenance treatment (OMT) in patients with stage IV soft tissue sarcoma (STS). (Klingebiel T, Boos J, Beske F, et al. Treatment of children with metastatic soft tissue sarcoma with oral maintenance compared to high dose chemotherapy: report of the HD CWS-96 trial. Pediatr Blood Cancer. 2008;50(4):739-745. doi:10.1002/pbc.21494)			New PD	
PD						MMT95	MMT 95 Study For Rhabdomyosarcoma and Other Malignant Soft Tissue Tumors of Childhood. This randomized phase III trial is studying surgery followed by different regimens of combination chemotherapy given together with radiation therapy and/or additional surgery to compare how well they work in treating patients with soft tissue sarcoma. (ClinicalTrials.gov Identifier: NCT00002898)			New PD	
VD	TREATMENT_ARM	Enum		A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.		_undefined_	_undefined_	_undefined_			
PD						ARST0331:Regimen I	Patients received treatment in the following course sequence: 1) VAC chemotherapy comprising vincristine sulfate IV over 1 minute on day 1 of weeks 1-9 and dactinomycin IV over 1 minute and cyclophosphamide IV over 1 hour on day 1 of weeks 1, 4, 7, and 1; 2) VA chemotherapy comprising vincristine sulfate IV over 1 minute on day 1 of weeks 13-21 and dactinomycin IV over 1 minute on day 1 of weeks 13, 16, 19, and 22 (dactinomycin is omitted during radiation therapy); 3) Radiation therapy, 5 days a week, beginning on week 13 and continuing for 4-7 weeks, depending on prescribed dose.			New PD	
PD						ARST0331:Regimen II	Patients received treatment in the following course sequence: 1) VAC chemotherapy and radiation therapy as in regimen I; 2) VA chemotherapy comprising vincristine sulfate IV over 1 minute on day 1 of weeks 13-21, 25-33, and 37-45 and dactinomycin IV over 1 minute on day 1 of weeks 13, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, and 46 (dactinomycin is omitted during radiation therapy).			New PD	
PD						ARST0431:High Risk Rhabdomyosarcoma	Patients received treatment in the following course sequence: 1) Parameningeal (without intracranial extension) and paraspinal tumors receive chemotherapy starting Week 1 and begin radiation therapy at Week 20; 2) Weeks 1-6: vincristine sulfate and irinotecan hydrochloride; 3) Weeks 7-34: vincristine sulfate and irinotecan hydrochloride, Cyclophosphamide with MESNA, Doxorubicin hydrochloride, Etoposide, Ifosfamide with MESNA; 4) Weeks 35-54: vincristine sulfate, Dactinomycin, irinotecan hydrochloride and Cyclophosphamide with MESNA and Filgrastim; 5) Radiation therapy beginning at Week 20; 6) Second look conventional surgery: Surgical resection other than biopsy will be applicable for the majority of patients.			New PD	
PD						ARST0531:Arm I (Chemotherapy, Radiotherapy)	Patients randomized with the following course sequence: 1) VAC chemotherapy comprising vincristine IV over 1 minute on day 1 of weeks 1-13, 16, 19-25, 28, 31-37, and 40; 2) Dactinomycin IV over 1-5 minutes on day 1 of weeks 1, 4, 13, 16, 19, 22, 25, 28, 31, 34, 37,and 40; 3) Cyclophosphamide IV over 1 hour on day 1 of weeks 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, and 40; 4) Patients may also undergo radiotherapy 5 days a week for 4-6 weeks beginning in week 4.			New PD	
PD						ARST0531:Arm II (Chemotherapy, Radiotherapy)	Patients randomized with the following course sequence: 1) VAC chemotherapy alternating with VI chemotherapy comprising vincristine IV over 1 minute on day 1 of weeks 1-13, 16, 17, 19, 20, 22-26, 28, 31-34, 37, 38, and 40; 2) Dactinomycin IV over 1-5 minutes on day 1 of weeks 1, 13, 22, 28, 34, and 40; 3) Cyclophosphamide IV over 1 hour on day 1 of weeks 1,10, 13, 22, 28, 34, and 40; 4) Irinotecan hydrochloride IV over 1 hour on days 1-5 of weeks 4, 7, 16, 19, 25, 31, and 37; 5) Patients may also undergo radiotherapy 5 days a week for 4-6 weeks beginning in week 4.			New PD	
PD						ARST08P1:Group 1 (Chemotherapy, Radiation Therapy, Cixutumumab)	Patients randomized with the following course sequence: 1) Vincristine sulfate IV over 1 minute on day 1 of weeks 1-5, 7, 8, 11, 12, 15, 16, 20-24, 28, 29, 32, 33, 35, 38, 41-44, 47, 48, 50, and 51; 2) Irinotecan hydrochloride IV over 90 minutes on days 1-5 of weeks 1, 4, 20, 23, 47, and 50; 3) Ifosfamide IV over 1 hour and etoposide IV over 1-2 hours on days 1-5 of weeks 9, 13, 17, 26, and 30; 4) Doxorubicin hydrochloride IV over 1-15 minutes on days 1 and 2 of weeks 7, 11, 15, 28, and 32; 5) Cyclophosphamide IV over 30-60 minutes on day 1 of weeks 7, 11, 15, 28, 32, 35, 38, 41, and 44; 6) Dactinomycin IV over 1-5 minutes on day 1 of weeks 35, 38, 41, and 44; 7) Cixutumumab IV over 1 hour on day 1 of weeks 1-51; 8) Patients also undergo radiation therapy on days 1-5 of weeks 20-24.			New PD	
PD						D9602:Subgroup A	Patients received treatment in the following course sequence: 1) Vincristine plus dactinomycin (VA).			New PD	
PD						D9602:Subgroup B	Patients received treatment in the following course sequence: 1) Vincristine (VA) plus cyclophosphamide.			New PD	
PD						D9802	Patients randomized with the following course sequence: 1) Bevacizumab on day 1 or temsirolimus on days 1, 8, and 15 of each 21-day treatment cycle, together with vinorelbine on days 1 and 8, and cyclophosphamide on day 1 for a maximum of 12 cycles; 2) Local tumor control with surgery and/or radiation therapy was permitted after 6 weeks of treatment.			New PD	
PD						D9803	Patients randomized with the following course sequence: 1) Bevacizumab on day 1 or temsirolimus on days 1, 8, and 15 of each 21-day treatment cycle, together with vinorelbine on days 1 and 8, and cyclophosphamide on day 1 for a maximum of 12 cycles; 2) Local tumor control with surgery and/or radiation therapy was permitted after 6 weeks of treatment.			New PD	
PD						RMS2005	Patients randomized with the following course sequence: 1) 9 cycles of IVA +/− doxorubicin, surgery, and/or radiotherapy.			New PD	
PD						MTS2008	Patients received treatment in the following course sequence: 1) Four cycles of ifosfamide, vincristine, and actinomycin D (IVA) plus doxorubicin, five cycles of IVA, and 12 cycles of maintenance chemotherapy (low-dose cyclophosphamide and vinorelbine).			New PD	
PD						ICG RMS96	Patients received treatment in the following course sequence: 1) Radiation therapy (RT) 			New PD	
PD						RMS 4.99	Patients received treatment in the following course sequence: 1) Three cycles of initial standard chemotherapy; 2) One course of cyclophosphamide and etoposide to obtain peripheral blood stem cells (PBSC); 3) Three consecutive high-dose combinations followed by PBSC rescue; 4) Surgery and/or radiotherapy, after which a final maintenance treatment with six courses of vincristine, actinomycin D and cyclophosp.hamide was administered			New PD	
PD						CWS-IV-2002	Patients received treatment in the following course sequence: 1) Two courses of topotecan and carboplatin; 2) Two consecutive cycles of ifosfamide, vincristine, actinomycin D (I3VA), ifosfamide, vincristine, adriamycin (I3VAd), and TC			New PD	
PD						CWS2002P:LR	Patients received treatment in the following course sequence: 1) Vincristine (VCR), dactinomycin (ACTO-D)			New PD	
PD						CWS2002P:SR	Patients received treatment in the following course sequence: 1) Vincristine (VCR), dactinomycin (ACTO-D) and ifosfamide (IFO)			New PD	
PD						CWS2002P:HR	Patients received treatment in the following course sequence: 1) Vincristine (VCR), dactinomycin (ACTO-D), ifosfamide (IFO) and doxorubicin; 2) Low-dose cyclophosphamide and vinblastine maintenance therapy (MT) over 6 months.			New PD	
PD						CWS2002P:VHR	Patients received treatment in the following course sequence: 1) Vincristine (VCR), dactinomycin (ACTO-D), ifosfamide (IFO) and doxorubicin; 2) Low-dose cyclophosphamide and vinblastine maintenance therapy (MT) over 6 months.			New PD	
PD						CWS91	Patients received treatment in the following course sequence: 1) Etoposide, vincristine, dactinomycin, ifosfamide, and doxorubicin (EVAIA)			New PD	
PD						CWS96:High Dose Therapy (HDT)	Patients received treatment in the following course sequence: 1) Carboplatin, etoposide, vincristine, actinomycin D, ifosfamide, and epirubicin; 2) Cycle of thiotepa (600 mg/m2) plus cyclophosphamide (4,500 mg/m2) and melphalan (120 mg/m2) plus etoposide (1,800 mg/m2)			New PD	
PD						CWS96:Oral Maintenance Therapy (OMT)	Patients received treatment in the following course sequence: 1) Carboplatin, etoposide, vincristine, actinomycin D, ifosfamide, and epirubicin; 2) Four cycles trofosfamide (10 days 2 × 75 mg/m2/day) plus etoposide (10 days 2 × 25 mg/m2/day), and 4 cycles trofosfamide (10 days 2 × 75 mg/m2/day) plus idarubicin (10 days 4 × 5 mg/m2).			New PD	
PD						MMT95	Patients randomized with the following course sequence: 1) Ifosfamide, vincristine, and dactinomycin (IVA) or a six-drug combination (IVA plus carboplatin, epirubicin, and etoposide) both delivered over 27 weeks.			New PD	
VD	CENSOR_STATUS	Enum		Censor Status		_undefined_	_undefined_	_undefined_			
PD						Subject is censored (i.e. has had no events(s)					
PD						Subject has had one or more events					
PD						Unknown					
											
											
DD	Protocol										
TD	Time Period									New TD	
TG	One row per subject per time period type										
VD	HONEST_BROKER_SUBJECT_ID	String		The identifier assigned to the subject by the honest broker. An individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a "re-identification code"), however the information linking this re- identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.	ncit:C168949	_undefined_	_undefined_	_undefined_		New VD	
VD	SUBMITTER_ID	String		An ID provided by the data contributor that identifies a unique time period and that is referenced throughout subsequent tabels in the TIME_PERIOD_SUBMITTER_ID variables.		_undefined_	_undefined_	_undefined_		New VD	
VD	PARENT_SUBMITTER_ID	String		The SUBMITTER_ID of the time period in whose context a subsequent time period takes place. For example, multiple treatment courses occuring the "Initial Diagnosis" period would each reference the SUBMITTER_ID of the "Initial Diagnosis" period as their PARENT_SUBMITTER_ID.		_undefined_	_undefined_	_undefined_		New VD	
VD	TIME_PERIOD_TYPE	Enum		The type of time period being reported.		_undefined_	_undefined_	_undefined_		New VD	
PD						Disease Phase	The stage or period of an individual's disease.	ncit:C168878			
PD						Course	The type of protocol treatment course administered with respect to Course Timing.	ncit:C187095			
VD	DISEASE_PHASE	Enum		The phase of the cancer treatment process during which relevant observations were recorded. This variable is used across domains to frame the timing of these longitudinal observations and reduce the number of redundant variables needed to report similar concepts (see "Disease Phase Timing and Course Table" in the documentation for additional guidance).	ncit:C168878	_undefined_	_undefined_	_undefined_		[rms_v1.0].[Disease Phase Timing].[DISEASE_PHASE] skos:exactMatch [rms_v2.0].[Time Period].[DISEASE_PHASE]	
PD						Initial Diagnosis	The first diagnosis of the individual's condition.	ncit:C156813			
PD						Relapse	The return of a disease after a period of remission.	ncit:C38155			
PD						Progression	A process that manifests as the worsening of a disease over time.	ncit:C17747			
VD	COURSE	Enum		The protocol treatment "course" during which relevant observations were recorded. This variable is used across domains to frame the timing of these longitudinal observations and reduce the number of redundant variables needed to report similar concepts (see "Disease Phase Timing and Course Table" in the documentation for additional guidance).	ncit:C168807	_undefined_	_undefined_	_undefined_		[rms_v1.0].[Course Timing].[COURSE] skos:exactMatch [rms_v2.0].[Time Period].[COURSE]	
PD						Prephase	A chemotherapy treatment administered prior to the definitive chemotherapy treatment.	ncit:C168826			
PD						Induction	The first choice of treatment for a particular type of cancer.	ncit:C158876			
PD						Intensification	A second round of intense chemotherapy as part of consolidation therapy.	ncit:C173105			
PD						Consolidation	Treatment that is given after initial therapy to kill any remaining cancer cells.	ncit:C15679			
PD						Maintenance	Continuation of treatment for an extended period of time to prevent relapse.	ncit:C15688			
VD	TIME_PERIOD_NUMBER	Integer		This variable indicates the ordinal numbering of time periods of the same TIME_PERIOD_TYPE within its various subgroups (e.g., Relapse 1, Relapse 2, Relapse 3, etc.). The observations across domains can therefore be organized longitudinally without the need for specific dates.		_undefined_	_undefined_	_undefined_		[rms_v1.0].[Disease Phase Timing].[DISEASE_PHASE_NUMBER] skos:broadMatch [rms_v2.0].[Time Period].[TIME_PERIOD_NUMBER] | [rms_v1.0].[Course Timing].[COURSE_NUMBER] skos:broadMatch [rms_v2.0].[Time Period].[TIME_PERIOD_NUMBER]	
VD	YEAR_AT_START	Integer		The year at the start of the indicated time period.		_undefined_	_undefined_	_undefined_		[rms_v1.0].[Disease Phase Timing].[YEAR_AT_DISEASE_PHASE] skos:exactMatch [rms_v2.0].[Time Period].[YEAR_AT_START]	
VD	AGE_AT_START	Integer		The age (in days) of the patient at the start of the reported time period.		_undefined_	_undefined_	_undefined_		[rms_v1.0].[Disease Phase Timing].[AGE_AT_DISEASE_PHASE] skos:broadMatch [rms_v2.0].[Time Period].[AGE_AT_START] | [rms_v1.0].[Course Timing].[AGE_AT_COURSE_START] skos:broadMatch [rms_v2.0].[Time Period].[AGE_AT_START]	
VD	AGE_AT_END	Integer		The age (in days) of the patient at the end of the reported time period.		_undefined_	_undefined_	_undefined_		[rms_v1.0].[Course Timing].[AGE_AT_COURSE_END] skos:exactMatch [rms_v2.0].[Time Period].[AGE_AT_END]	
											
											
DD	Demographics										
TD	Demographics										
TG	One row per subject										
VD	HONEST_BROKER_SUBJECT_ID	String		The identifier assigned to the subject by the honest broker. An individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a "re-identification code"), however the information linking this re- identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.	ncit:C168949	_undefined_	_undefined_	_undefined_		New VD	
VD	SEX	Enum		The assemblage of physical properties or qualities by which male is distinguished from female; the physical difference between male and female; the distinguishing peculiarity of male or female.		_undefined_	_undefined_	_undefined_			
PD						Male	A person who belongs to the sex that normally produces sperm. The term is used to indicate biological sex distinctions, cultural gender role distinctions, or both.	C20197			
PD						Female	A person who belongs to the sex that normally produces ova. The term is used to indicate biological sex distinctions, or cultural gender role distinctions, or both.	C16576			
PD						Unknown	Reported as unknown by the data contributor.	C17998			
PD						Not Reported	Not provided or available.	C43234			
VD	RACE	Enum		An arbitrary classification of a taxonomic group that is a division of a species. It usually arises as a consequence of geographical isolation within a species and is characterized by shared heredity, physical attributes and behavior, and in the case of humans, by common history, nationality, or geographic distribution.		_undefined_	_undefined_	_undefined_			
PD						American Indian or Alaska Native	A person having origins in any of the original peoples of North and South America (including Central America) and who maintains tribal affiliation or community attachment. (OMB)	C41259			
PD						Asian	A person having origins in any of the original peoples of the Far East, Southeast Asia, or the Indian subcontinent, including for example, Cambodia, China, India, Japan, Korea, Malaysia, Pakistan, the Philippine Islands, Thailand, and Vietnam. (OMB)	C41260			
PD						Black or African American	A person having origins in any of the Black racial groups of Africa. Terms such as "Haitian" or "Negro" can be used in addition to "Black or African American". (OMB)	C16352			
PD						Multiracial	Having ancestors of several or various races.	C67109			
PD						Native Hawaiian or Other Pacific Islander	A person having origins in any of the original peoples of Hawaii, Guam, Samoa, or other Pacific Islands. (OMB)	C41219			
PD						White	A person having origins in any of the original peoples of Europe, the Middle East, or North Africa. (OMB)	C41261			
PD						Other	Different than the one(s) previously specified or mentioned.	C17649			
PD						Unknown	Reported as unknown by the data contributor.	C17998			
PD						Not Reported	Not provided or available.	C43234			
VD	ETHNICITY	Enum		A social group characterized by a distinctive social and cultural tradition that is maintained from generation to generation. Members share a common history and origin and a sense of identification with the group. They have similar and distinctive features in their lifestyle habits and shared experiences. They often have a common genetic heritage which may be reflected in their experience of health and disease.		_undefined_	_undefined_	_undefined_			
PD						Hispanic or Latino	A person of Cuban, Mexican, Puerto Rican, South or Central American, or other Spanish culture or origin, regardless of race. The term, "Spanish origin," can be used in addition to "Hispanic or Latino." (OMB)	C17459			
PD						Not Hispanic or Latino	A person not of Cuban, Mexican, Puerto Rican, South or Central American, or other Spanish culture or origin, regardless of race.	C41222			
PD						Unknown	Reported as unknown by the data contributor.	C17998			
PD						Not Reported	Not provided or available.	C43234			
											
											
DD	Demographics										
TD	Survival Characteristics										
TG	One row per subject per cause of death, per treatment type, per cause of death detail										
VD	HONEST_BROKER_SUBJECT_ID	String		The identifier assigned to the subject by the honest broker. An individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a "re-identification code"), however the information linking this re- identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.	ncit:C168949	_undefined_	_undefined_	_undefined_		New VD	
VD	AGE_AT_LKSS	Integer		Age in Days at Last Known Survival Status		_undefined_	_undefined_	_undefined_			
VD	LKSS	Enum		The individual's last known survival status.		_undefined_	_undefined_	_undefined_			
PD						Alive					
PD						Dead					
PD						Unknown					
VD	CAUSE_OF_DEATH	Enum		The circumstance or condition that results in the death of a living being.		_undefined_	_undefined_	_undefined_			
PD						Disease Progression			Note: If multiple causes of death, include one observation per cause of death.  However, only one cause of death can have the varaiable CAUSE_OF_DEATH_RANKING=Primary.		
PD						Treatment-Related Mortality					
PD						Secondary Malignancy					
PD						Other					
PD						Unknown					
PD						Not Reported					
VD	CAUSE_OF_DEATH_OTHER	Enum		Cause of Death Other		_undefined_	_undefined_	_undefined_			
											
											
DD	Testing										
TD	Molecular Analysis										
TG	One row per subject per molecular analysis method per molecular abnormality										
VD	HONEST_BROKER_SUBJECT_ID	String		The identifier assigned to the subject by the honest broker. An individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a "re-identification code"), however the information linking this re- identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.	ncit:C168949	_undefined_	_undefined_	_undefined_		New VD	
VD	AGE_AT_MOLECULAR_ANALYSIS	Integer		Age of subject (in days) when molecular analysis was performed.		_undefined_	_undefined_	_undefined_			
VD	MOLECULAR_ABNORMALITY	Enum		A molecular or cytogenic abnormality which occurs in either human disease states or disease models.		_undefined_	_undefined_	_undefined_			
PD						PAX3-FOXO1			Note: If multiple molecular abnormalities, include one observation per molecular abnormality.		
PD						PAX7-FOXO1					
PD						PAX3-Other					
PD						Other-FOXO1					
VD	VARIANT_TYPE	Enum		A variation in or modification of the molecular sequence of a gene or gene product.		_undefined_	_undefined_	_undefined_			
PD						Translocation	Any type of genetic recombination involving exchange of DNA between non-homologous chromosomes, which often occurs as the result of non-homologous end-joining of broken DNA strands. Chromosomal translocation is involved in repairing broken DNA and in maintaining cell viability at the expense of long term genomic stability. This process is is associated with particular types of leukemia, infertility and Down Syndrome.	C25756			
PD						Inversion	A structural change in genomic DNA where the 5' to 3' order of a nucleotide sequence is completely reversed to the 3' to 5' order relative to its adjacent sequences. This inversion is termed either pericentric, if it includes the centromere of a chromosome, or pancentric, if it excludes the centromere. An inversion mutation abnormality may be heritable or occur somatically.	C45589			
PD						Mutation	Any transmissible change in the genetic material of an organism, which can result from radiation, viral infection, transposition, treatment with mutagenic chemicals and errors during DNA replication or meiosis. The effects of mutation range from single base changes to loss or gain of complete chromosomes. As many of the simpler alterations to DNA may be repaired, such changes are only heritable once the change is fixed in the DNA by the process of replication. Mutations may be associated with genetic diversity or with pathologies including cancer.	C45576			
PD						Single Nucleotide Variant	A variation of a single nucleotide at a specific location of the genome due to base substitution, which is found at any frequency in the population.	C146674			
PD						Copy Integer Alteration	Variation in the Integer of copies of a particular sequence within the genetic material of an individual. Large-scale copy Integer polymorphisms are common and widely distributed in the human genome.	C40207			
PD						Rearrangement	Any DNA sequence rearrangement that results in the creation of a novel protein-coding capacity. Within certain genes, gene rearrangement is a normal part of development, facilitating the affinity maturation of B and T lymphocytes as well as class switching of immunoglobulins.	C16611			
PD						Deletion	Any rearrangement to the genomic content that results in the loss of one or more nucleotides of DNA. Deletions are generally irreversible rearrangements. They may alter the reading frame of a gene, or may result in loss of large chromosomal regions.	C19296			
PD						Amplification	Addition of extra material.	C25418			
PD						Other	Different than the one(s) previously specified or mentioned.	C17649			
PD						Unknown	Reported as unknown by the data contributor.	C17998			
PD						Not Reported	Not provided or available.	C43234			
VD	CHROMOSOME	String		One of the bodies in the cell nucleus that is the bearer of genes, has the form of a delicate chromatin filament during interphase, contracts to form a compact cylinder segmented into two arms by the centromere during metaphase and anaphase stages of cell division, and is capable of reproducing its physical and chemical structure through successive cell divisions.		_undefined_	_undefined_	_undefined_			
VD	GENE1	String		The gene symbol that represents either a single gene that has a mutation or the gene that comprises the 5' portion of the coding sequence involved in a fusion gene mutation.		_undefined_	_undefined_	_undefined_			
VD	GENE2	String		The gene symbol that represents the gene that comprises the 3' portion of the coding sequence for a fusion gene.		_undefined_	_undefined_	_undefined_			
VD	MOLECULAR_ABNORMALITY_RESULT	Enum		An indicator for whether a molecular analysis procedure was performed and whether the assay detected a molecular abnormality.		_undefined_	_undefined_	_undefined_			
PD						Positive	A finding of abnormality following an examination or observation confirming something, such as the presence of a disease, condition, or microorganism.	C38758			
PD						Negative	A finding of normality following an examination or investigation looking for the presence of a microorganism, disease, or condition.	C38757			
PD						Not Done	Indicates a task, process or examination that has either not been initiated or not been completed.	C49484			
PD						Unknown	Reported as unknown by the data contributor.	C17998			
VD	ANAPLASIA	Enum		Anaplasia		_undefined_	_undefined_	_undefined_			
PD						Absent					
PD						Present					
PD						Unknown					
VD	ANAPLASIA_EXTENT	Enum		Anaplasia Extent		_undefined_	_undefined_	_undefined_			
PD						Diffuse					
PD						Focal					
PD						Unknown					
											
											
DD	Disease Attributes										
TD	Diagnosis										
TG	One row per subject per diagnosis										
VD	HONEST_BROKER_SUBJECT_ID	String	2 - contributors should prioritize inclusion if resources are available	The identifier assigned to the subject by the honest broker. An individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a "re-identification code"), however the information linking this re- identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.	ncit:C168949	_undefined_	_undefined_	_undefined_		New VD	
VD	AGE_AT_DIAG_ASSESSMENT	Integer	2 - contributors should prioritize inclusion if resources are available	The age (in days) of the subject at the time of this diagnostic assessment.	ncit:C175004	_undefined_	_undefined_	_undefined_		[rms_v1.0].[Histology].[AGE_AT_HIST_ASSESSMENT] skos:exactMatch [rms_v2.0].[Histology].[AGE_AT_DIAG_ASSESSMENT]	
VD	DIAGNOSIS_BASIS	Enum	2 - contributors should prioritize inclusion if resources are available	The type of diagnosis used for determining the medical condition.		_undefined_	_undefined_	_undefined_		New VD	
PD						Histological	Pertaining to the combined microscopic physical features of cells and their surrounding extracellular environment in tissues.	ncit:C25526			
VD	DIAGNOSIS	Enum	2 - contributors should prioritize inclusion if resources are available	The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation.	ncit:C15220	_undefined_	_undefined_	_undefined_		[rms_v1.0].[Histology].[HISTOLOGY] skos:exactMatch [rms_v2.0].[Histology].[DIAGNOSIS]	
PD						Alveolar rhabdomyosarcoma (ARMS)			Note: If multiple histological findings, include one observation per histological finding.		
PD						Botryoid rhabdomyosarcoma (BRMS)					
PD						Embryonal rhabdomyosarcoma (ERMS)					
PD						Pleomorphic rhabdomyosarcoma (PRMS)					
PD						Rhabdomyosarcoma (RMS), not classifiable					
PD						Rhabdomyosarcoma (RMS), inadequate tissue for classification					
PD						Rhabdomyosarcoma (RMS), with Mixed Embryonal and Alveolar Features					
PD						Spindle cell					
PD						Unknown					
PD						Not Reported					
											
											
DD	Disease Attributes										
TD	Staging										
TG	One row per subject per staging assessment										
VD	HONEST_BROKER_SUBJECT_ID	String	2 - contributors should prioritize inclusion if resources are available	The identifier assigned to the subject by the honest broker. An individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a "re-identification code"), however the information linking this re- identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.	ncit:C168949	_undefined_	_undefined_	_undefined_		New VD	
VD	AGE_AT_STAGING	Integer		Age of subject (in days) at the time of the staging assessment.		_undefined_	_undefined_	_undefined_			
VD	TNM_FINDING	Enum		TNM Finding		_undefined_	_undefined_	_undefined_			
PD						Favorable Site, M0			Note: Tied to AGE_AT_STAGING.		
PD						Other site, any T, a, N0, M0					
PD						Other site, any T, a, N1, M0, any T, b, N0/N1, M0					
PD						Metastases, ML					
PD						Unknown					
PD						Not Reported					
VD	GROUP	Enum		IRS Surgical-Pathologic Grouping System		_undefined_	_undefined_	_undefined_		[rms_v1.0].[Staging].[IRS_GROUP] skos:exactMatch [rms_v2.0].[Staging].[GROUP]	
PD						IRS, Group I			Note: Tied to AGE_AT_STAGING.	[rms_v1.0].[Staging].[IRS_GROUP].[Group I] skos:exactMatch [rms_v2.0].[Staging].[GROUP].[IRS, Group I]	
PD						IRS, Group IIA				[rms_v1.0].[Staging].[IRS_GROUP].[Group IIA] skos:exactMatch [rms_v2.0].[Staging].[GROUP].[IRS, Group IIA]	
PD						IRS, Group IIB				[rms_v1.0].[Staging].[IRS_GROUP].[Group IIB] skos:exactMatch [rms_v2.0].[Staging].[GROUP].[IRS, Group IIB]	
PD						IRS, Group IIC				[rms_v1.0].[Staging].[IRS_GROUP].[Group IIC] skos:exactMatch [rms_v2.0].[Staging].[GROUP].[IRS, Group IIC]	
PD						IRS, Group II NOS				[rms_v1.0].[Staging].[IRS_GROUP].[Group II, NOS] skos:exactMatch [rms_v2.0].[Staging].[GROUP].[IRS, Group II NOS]	
PD						IRS, Group III				[rms_v1.0].[Staging].[IRS_GROUP].[Group III] skos:exactMatch [rms_v2.0].[Staging].[GROUP].[IRS, Group III]	
PD						IRS, Group IV				[rms_v1.0].[Staging].[IRS_GROUP].[Group IV] skos:exactMatch [rms_v2.0].[Staging].[GROUP].[IRS, Group IV]	
PD						Unknown					
PD						Not Reported					
											
											
DD	Disease Attributes										
TD	Disease Site Assessment									[rms_v1.0].[Tumor Assessment] skos:exactMatch [rms_v2.0].[Disease Site Assessment]	
TG	One row per subject per evaluation and per lesion (local, regional or metastatic)										
VD	HONEST_BROKER_SUBJECT_ID	String	2 - contributors should prioritize inclusion if resources are available	The identifier assigned to the subject by the honest broker. An individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a "re-identification code"), however the information linking this re- identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.	ncit:C168949	_undefined_	_undefined_	_undefined_		New VD	
VD	AGE_AT_DISEASE_SITE_ASSESSMENT	Integer	2 - contributors should prioritize inclusion if resources are available	The age (in days) of the subject at the time of this disease site assessment.	ncit:C174997	_undefined_	_undefined_	_undefined_		[rms_v1.0].[Tumor Assessment].[AGE_AT_TUMOR_ASSESSMENT] skos:exactMatch [rms_v2.0].[Disease Site Assessment].[AGE_AT_DISEASE_SITE_ASSESSMENT]	
VD	CLASSIFICATION	Enum	2 - contributors should prioritize inclusion if resources are available	The classification of a tumor based primarily on histopathological characteristics.	ncit:C174459	_undefined_	_undefined_	_undefined_		[rms_v1.0].[Tumor Assessment].[TUMOR_CLASSIFICATION] skos:exactMatch [rms_v2.0].[Disease Site Assessment].[CLASSIFICATION]	
PD						Primary	A tumor at the original site of origin.	ncit:C8509			
PD						Regional	A disease or condition that extends beyond the site and spreads into adjacent tissues and regional lymph nodes.	ncit:C41844			
PD						Metastatic	A term referring to the clinical or pathologic observation of a tumor extension from its original site of growth to another anatomic site.	ncit:C14174			
PD						Unknown	Reported as unknown by the data contributor.	ncit:C17998			
PD						Not Reported	Not provided or available.	ncit:C43234			
VD	SITE	Enum	2 - contributors should prioritize inclusion if resources are available	The anatomical site on which the disease is assessed.	ncit:C166232	_undefined_	_undefined_	_undefined_	Note: If there were multiple primary sites, include one observation per primary site.	[rms_v1.0].[Tumor Assessment].[TUMOR_SITE] skos:exactMatch [rms_v2.0].[Disease Site Assessment].[SITE]	
PD						Abdomen	The cavity located between the lungs and pelvis. It contains the lower esophagus, stomach, pancreas, intestines, liver, gallbladder and spleen.	ncit:C12664			
PD						Anal/Perianal	The lower opening of the digestive tract, lying in the cleft between the buttocks, through which fecal matter is extruded. | The skin area around the anus.	ncit:C43362|ncit:C99148			
PD						Bladder	The distensible sac-like organ that functions as a reservoir of urine, collecting from the kidneys and eliminating via the urethra.	ncit:C12414			
PD						Bladder/Prostate	The distensible sac-like organ that functions as a reservoir of urine, collecting from the kidneys and eliminating via the urethra. | The walnut shaped accessory sex gland of the male reproductive system. It is located in the pelvis just below the bladder, surrounding the prostatic part of the urethra. The prostate gland secretes a fluid which is part of the semen.	ncit:C12414|ncit:C12410			
PD						Bone	The structural organ comprised of specialized connective tissue that forms the skeletal components of the body.	ncit:C12366			
PD						Bone Marrow	The tissue occupying the spaces of bone. It consists of blood vessel sinuses and a network of hematopoietic cells which give rise to the red cells, white cells, and megakaryocytes.	ncit:C12431			
PD						Brain	An organ composed of grey and white matter containing billions of neurons that is the center for intelligence and reasoning. It is protected by the bony cranium.	ncit:C12439			
PD						Cervix	The lower part of the uterus occupying the region between the isthmus of the uterus and the vagina. It is divided into supravaginal and vaginal portions.	ncit:C12311			
PD						Cheek	The fleshy part of the face bounded by the eyes, nose, ear, and jaw line.	ncit:C13070			
PD						Distant Lymph Nodes	A bean-shaped organ surrounded by a connective tissue capsule. It is part of the lymphatic system and is found throughout the body. It is composed predominantly of lymphocytes and its main function is immune protection.	ncit:C12745			
PD						Eyelid	A thin membrane of skin with the purpose of covering and protecting an eye.	ncit:C12713			
PD						Foot	The structure found below the ankle joint required for locomotion.	ncit:C32622			
PD						Forearm	The structure on the upper limb, between the elbow and the wrist.	ncit:C32628			
PD						Hand	The distal portion of the upper extremity. It consists of the carpus, metacarpus, and digits.	ncit:C32712			
PD						Hypopharynx	The lower part of the pharynx that connects to the esophagus.	ncit:C12246			
PD						Infratemporal Fossa/Pterygopalatine	The infratemporal fossa, also known as the pterygopalatine fossa, is a complex anatomical region located in the human skull, specifically on the lateral aspect of the skull base. It is situated deep within the skull, adjacent to the maxillary (upper jaw) and sphenoid bones. This anatomical area is crucial in housing and providing passage for various important structures, including nerves, blood vessels, and muscles.				
PD						Kidney	One of the two bean-shaped organs located on each side of the spine in the retroperitoneum. The right kidney is located below the liver and the left kidney below the diaphragm. The kidneys filter and secrete metabolic products and minerals from the blood, thus maintaining homeostasis. On the superior pole of each kidney there is an adrenal gland. Each kidney and adrenal gland is surrounded by fat.	ncit:C12415			
PD						Knee	A joint connecting the lower part of the femur with the upper part of the tibia. The lower part of the femur and the upper part of the tibia are attached to each other by ligaments. Other structures of the knee joint include the upper part of the fibula, located below and parallel to the tibia, and the patella which moves as the knee bends.	ncit:C32898			
PD						Larynx	The cartilaginous structure of the respiratory tract between the pharynx and the trachea. It contains elastic vocal cords required for sound production.	ncit:C12420			
PD						Leg	The portion of the lower extremity between the knee and the ankle. For clinical purposes this term is also used to refer to the whole inferior limb.	ncit:C32974			
PD						Liver/Biliary Tract	A triangular-shaped organ located under the diaphragm in the right hypochondrium. It is the largest internal organ of the body, weighting up to 2 kg. Metabolism and bile secretion are its main functions. It is composed of cells which have the ability to regenerate. | The system that transports bile from the hepatocytes in the liver to the small intestine. It is comprised of the intrahepatic bile ducts, hepatic ducts, common bile duct, cystic duct, and the gallbladder.	ncit:C12392|ncit:C12678			
PD						Lower Leg	The lower leg is the portion of the lower limb, also known as the leg, that extends from the knee joint down to the ankle joint. It is located between the upper leg (thigh) and the foot and is an essential anatomical structure that facilitates movement, weight-bearing, and locomotion.				
PD						Lung	One of a pair of viscera occupying the pulmonary cavities of the thorax, the organs of respiration in which aeration of the blood takes place. As a rule, the right lung is slightly larger than the left and is divided into three lobes (an upper, a middle, and a lower or basal), while the left has two lobes (an upper and a lower or basal). Each lung is irregularly conical in shape, presenting a blunt upper extremity (the apex), a concave base following the curve of the diaphragm, an outer convex surface (costal surface), an inner or mediastinal surface (mediastinal surface), a thin and sharp anterior border, and a thick and rounded posterior border.	ncit:C12468			
PD						Middle Ear	The part of the ear including the eardrum and ossicles. The middle ear leads to the inner ear.	ncit:C12274			
PD						Nasal Cavity	The proximal portion of the respiratory passages on either side of the nasal septum lying between the floor of the cranium and the roof of the mouth and extending from the face to the pharynx. The nasal cavity is lined with ciliated mucosa, extending from the nares to the pharynx.	ncit:C12424			
PD						Nasopharynx	The part of the pharynx in the back of the throat, at and above the soft palate. The nasopharynx is continuous with the nasal passages.	ncit:C12423			
PD						Neck	The region that connects the head to the rest of the body.	ncit:C13063			
PD						Oral Cavity	The cavity located at the upper end of the alimentary canal, behind the teeth and gums that is bounded on the outside by the lips, above by the hard and soft palates and below by the tongue.	ncit:C12421			
PD						Orbit	The bony cavity of the skull which contains the eye, anterior portion of the optic nerve, ocular muscles and ocular adnexa. Seven bones contribute to the structure of the orbit: the frontal, maxillary, zygomatic, sphenoid, lacrimal, ethmoid, and palatine bones.	ncit:C12347			
PD						Oropharynx	The part of the pharynx between the soft palate and the upper portion of the epiglottis.	ncit:C12762			
PD						Ovary	One of the paired female reproductive glands containing the ova or germ cells; the ovary's stroma is a vascular connective tissue containing numbers of ovarian follicles enclosing the ova.	ncit:C12404			
PD						Paranasal Sinuses	Any one of the air-filled spaces within the ethmoid, frontal, maxillary, or sphenoid bones, which communicate with the nasal cavity.	ncit:C12763			
PD						Parapharyngeal Area	A cone-shaped lateral neck space with its base on the base of the skull and its apex at the hyoid bone.	ncit:C162818			
PD						Paraspinal	Pertaining to muscles and/or tissue adjacent to the spinal column.	ncit:C129461			
PD						Paratesticular	A small anatomical compartment that contains the testicular collecting system, and mesothelial and mesenchymal components that represent extensions of the abdominal cavity and retroperitoneum.	ncit:C162491			
PD						Parathyroid					
PD						Parotid	The largest of the three paired salivary glands, located in front of the ear.	ncit:C12427			
PD						Pelvis	The bony, basin-shaped structure formed by the hipbones and the base of the backbone supporting the lower limbs in humans.	ncit:C12767			
PD						Perineum	The area located between the anus and vulva in females, and anus and scrotum in males.	ncit:C33301			
PD						Pleural Effusion	Increased amounts of fluid within the pleural cavity. Symptoms include shortness of breath, cough, and chest pain. It is usually caused by lung infections, congestive heart failure, pleural and lung tumors, connective tissue disorders, and trauma.	ncit:C3331			
PD						Prostate	The walnut shaped accessory sex gland of the male reproductive system. It is located in the pelvis just below the bladder, surrounding the prostatic part of the urethra. The prostate gland secretes a fluid which is part of the semen.	ncit:C12410			
PD						Retroperitoneum	The back of the abdomen where the kidneys lie and the great blood vessels run.	ncit:C12298			
PD						Scalp	The skin which covers the top of the head and which is usually covered by hair.	ncit:C89807			
PD						Shoulder	The region of the body between the neck and the upper arm.	ncit:C25203			
PD						Soft Tissue	A general term comprising tissue that is not hardened or calcified; including muscle, fat, blood vessels, nerves, tendons, ligaments and fascia.	ncit:C12471			
PD						Thigh	A part of the lower limb, located between hip and knee.	ncit:C33763			
PD						Thorax	The division of the body lying between the neck and the abdomen.	ncit:C12799			
PD						Thyroid	An endocrine gland located at the base of the neck that produces and secretes thyroxine and other hormones. Thyroxine is important for metabolic control.	ncit:C12400			
PD						Trunk	The body excluding the head and neck and limbs.	ncit:C33816			
PD						Upper Arm	The portion of the upper extremity between the shoulder and the elbow. For clinical purposes this term is also used to refer to the whole superior limb.	ncit:C32141			
PD						Uterus	A hollow, thick-walled, muscular organ located within the pelvic cavity of a woman. Within the uterus the fertilized egg implants and the fetus develops during pregnancy.	ncit:C12405			
PD						Vagina	The female genital canal, extending from the uterus to the vulva.	ncit:C12407			
PD						Vulva	The external, visible part of the female genitalia surrounding the urethral and vaginal opening. The vulva includes the clitoris and inner as well as outer labia.	ncit:C12408			
PD						Other	Different than the one(s) previously specified or mentioned.	ncit:C17649			
PD						Unknown	Reported as unknown by the data contributor.	ncit:C17998			
PD						Not Reported	Not provided or available.	ncit:C43234			
VD	SITE_OTHER	String	2 - contributors should prioritize inclusion if resources are available	Specify the "Other" SITE.		_undefined_	_undefined_	_undefined_		[rms_v1.0].[Tumor Assessment].[TUMOR_SITE_OTHER] skos:exactMatch [rms_v2.0].[Disease Site Assessment].[SITE_OTHER]	
VD	TUMOR_SIZE	Enum	2 - contributors should prioritize inclusion if resources are available	The tumor size of the largest tumor.		_undefined_	_undefined_	_undefined_			
PD						<=5 cm	The size of the tumor is less than or equal to 5 centimeters.				
PD						>5 cm	The size of the tumor is greater than 5 centimeters.				
PD						Unknown	Reported as unknown by the data contributor.	ncit:C17998			
PD						Not Reported	Not provided or available.	ncit:C43234			
VD	DIAMETER1	Decimal	2 - contributors should prioritize inclusion if resources are available	The longest diameter of the tumor.	ncit:C96684	_undefined_	_undefined_	_undefined_		[rms_v1.0].[Tumor Assessment].[LONGEST_DIAM_DIM1] skos:exactMatch [rms_v2.0].[Disease Site Assessment].[DIAMETER1]	
VD	DIAMETER1_UNIT	Enum	2 - contributors should prioritize inclusion if resources are available	The unit of measure symbol associated with a biospecimen or tissue fragment dimension.		_undefined_	_undefined_	_undefined_		New VD	
PD						cm	A basic unit of length in the former CGS version of metric system, equal to one hundredth of a meter or approximately 0.393 700 787 inch.	ncit:C49668			
VD	DIAMETER2	Decimal	2 - contributors should prioritize inclusion if resources are available	The second longest diameter of the tumor.	ncit:C96684	_undefined_	_undefined_	_undefined_		[rms_v1.0].[Tumor Assessment].[LONGEST_DIAM_DIM2] skos:exactMatch [rms_v2.0].[Disease Site Assessment].[DIAMETER2]	
VD	DIAMETER2_UNIT	Enum	2 - contributors should prioritize inclusion if resources are available	The unit of measure symbol associated with a biospecimen or tissue fragment dimension.		_undefined_	_undefined_	_undefined_		New VD	
PD						cm	A basic unit of length in the former CGS version of metric system, equal to one hundredth of a meter or approximately 0.393 700 787 inch.	ncit:C49668			
VD	DIAMETER3	Decimal	2 - contributors should prioritize inclusion if resources are available	The third longest diameter of the tumor.	ncit:C16809	_undefined_	_undefined_	_undefined_		[rms_v1.0].[Tumor Assessment].[LONGEST_DIAM_DIM3] skos:exactMatch [rms_v2.0].[Disease Site Assessment].[DIAMETER3]	
VD	DIAMETER3_UNIT	Enum	2 - contributors should prioritize inclusion if resources are available	The unit of measure symbol associated with a biospecimen or tissue fragment dimension.		_undefined_	_undefined_	_undefined_		New VD	
PD						cm	A basic unit of length in the former CGS version of metric system, equal to one hundredth of a meter or approximately 0.393 700 787 inch.	ncit:C49668			
VD	INVASIVENESS	Enum	2 - contributors should prioritize inclusion if resources are available	Tumor Invasiveness		_undefined_	_undefined_	_undefined_			
PD						T1 Stage Finding	A clinical and/or pathologic primary tumor TNM finding indicating that the cancer is limited to the site of growth.	ncit:C48720			
PD						T2 Stage Finding	A general term that refers to a TNM finding of primary tumor growth beyond the level of in situ cancer, minimal subepithelial invasion, or minimal greatest diameter. The definition of T2 TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to primary tumor that is more than 2.0 cm, but not more than 5.0 cm in greatest dimension; for cutaneous melanoma it refers to primary tumor that is 1.01 to 2 mm in thickness, with or without ulceration; for colorectal cancer it refers to primary tumor with invasion into the muscularis propria; and for bladder cancer it refers to primary tumor with invasion into the muscle layer.	ncit:C48724			
PD						TX Stage Finding	A primary tumor TNM finding indicating that the status of the primary tumor cannot be assessed.	ncit:C48737			
PD						Unknown	Reported as unknown by the data contributor.	ncit:C17998			
PD						Not Reported	Not provided or available.	ncit:C43234			
VD	NODAL_PATHOLOGY	Enum		Pathological Determination of Regional Lymph Node Involvement		_undefined_	_undefined_	_undefined_			
PD						N0 Stage Finding					
PD						N1 Stage FInding					
PD						NX Stage Finding					
PD						Unknown					
PD						Not Reported					
VD	NODAL_CLINICAL	Enum		Clinical Determination of Regional Lymph Node Involvemen		_undefined_	_undefined_	_undefined_			
PD						N0 Stage Finding					
PD						N1 Stage FInding					
PD						NX Stage Finding					
PD						Unknown					
PD						Not Reported					
VD	PARAMENINGEAL_EXTENSION	Enum	2 - contributors should prioritize inclusion if resources are available	Is there evidence of parameningeal extension of the tumor, indicating the spread of a tumor or pathological process beyond the primary site to involve the tissues adjacent to the meninges (the protective coverings of the brain and spinal cord)?		_undefined_	_undefined_	_undefined_			
PD						Yes	The affirmative response to a question.	ncit:C49488			
PD						No	The non-affirmative response to a question.	ncit:C49487			
PD						Unknown	Reported as unknown by the data contributor.	ncit:C17998			
PD						Not Reported	Not provided or available.	ncit:C43234			
											
											
DD	Treatment										
TD	Radiation Therapy										
TG	One row per subject per radiation therapy administration										
VD	HONEST_BROKER_SUBJECT_ID	String	2 - contributors should prioritize inclusion if resources are available	The identifier assigned to the subject by the honest broker. An individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a "re-identification code"), however the information linking this re- identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.	ncit:C168949	_undefined_	_undefined_	_undefined_		New VD	
VD	AGE_AT_RT_START	Integer		Age of subject (in days) at the start of radiation therapy.		_undefined_	_undefined_	_undefined_			
VD	CLASSIFICATION	Enum		The classification of a tumor based primarily on histopathological characteristics.		_undefined_	_undefined_	_undefined_		[rms_v1.0].[Radiation Therapy].[TUMOR_CLASSIFICATION] skos:exactMatch [rms_v2.0].[Radiation Therapy].[CLASSIFICATION]	
PD						Primary	A tumor at the original site of origin.	C8509			
PD						Regional Nodes					
PD						Metastatic	A tumor that has spread from its original (primary) site of growth to another site, close to or distant from the primary site. Metastasis is characteristic of advanced malignancies, but in rare instances can be seen in neoplasms lacking malignant morphology.	C3261			
VD	SITE	Enum		Radiation Therapy Site		_undefined_	_undefined_	_undefined_		[rms_v1.0].[Radiation Therapy].[RT_SITE] skos:exactMatch [rms_v2.0].[Radiation Therapy].[SITE]	
PD						Pelvis					
PD						Neck					
PD						Retroperitoneum					
PD						Perineum					
PD						Ovary					
PD						Paratesticular					
PD						Abdomen					
PD						Kidney					
PD						Shoulder					
PD						Scalp					
PD						Upper Arm					
PD						Forearm					
PD						Hand					
PD						Thigh					
PD						Knee					
PD						Leg					
PD						Lower Leg					
PD						Foot					
PD						Brain					
PD						Paraspinal					
PD						Vagina					
PD						Eyelid					
PD						Orbit					
PD						Cheek					
PD						Hypopharynx					
PD						Larynx					
PD						Oral Cavity					
PD						Oropharynx					
PD						Parotid					
PD						Thyroid and Parathyroid					
PD						Middle Ear					
PD						Nasal Cavity and Paranasal Sinuses					
PD						Nasal Cavity					
PD						Paranasal Sinuses					
PD						Nasopharynx					
PD						Infratemporal Fossa/Pterygopalatine and Parapharyngeal Area					
PD						Infratemporal Fossa/Pterygopalatine					
PD						Parapharyngeal Area					
PD						Bladder					
PD						Prostate					
PD						Bladder/Prostate					
PD						Cervix					
PD						Uterus					
PD						Vulva					
PD						Thorax					
PD						Anal/Perianal					
PD						Trunk					
PD						Bone or Bone Marrow					
PD						Bone					
PD						Bone Marrow					
PD						Distant Lymph Nodes					
PD						Pleural Effusion					
PD						Soft Tissue					
PD						Liver/Biliary Tract					
PD						Lung					
PD						Other					
PD						Unknown					
PD						Not Reported					
VD	ENERGY_TYPE	Enum		Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.		_undefined_	_undefined_	_undefined_			
PD						Protons	A type of external beam radiation therapy using a beam of protons. It has the advantage of precisely localizing the radiation dose on the targeted tissue and avoiding damage to the healthy surrounding tissues.	C66897			
PD						Photon	A single unit of electromagnetic radiation, generally considered to be a discrete particle having no mass or charge.	C88112			
PD						Brachytherapy	A type of radiation therapy in which radioactive material is placed inside the body, into a tumor or body cavity.	C15195			
PD						Electrons					
PD						Unknown	Reported as unknown by the data contributor.	C17998			
VD	DOSE	Integer		The total radiation dose administered.		_undefined_	_undefined_	_undefined_		[rms_v1.0].[Radiation Therapy].[RT_DOSE] skos:exactMatch [rms_v2.0].[Radiation Therapy].[DOSE]	
VD	DOSE_UNIT	Enum		A unit of measurement of the dose of radiation received or absorbed.		_undefined_	_undefined_	_undefined_		[rms_v1.0].[Radiation Therapy].[RT_UNIT] skos:exactMatch [rms_v2.0].[Radiation Therapy].[DOSE_UNIT]	
PD						Gy	A SI derived unit of absorbed radiation dose. One gray is equal to an absorbed dose of one joule per kilogram of matter, or to 100 rads.	C18063			
											
											
DD	Treatment										
TD	Biopsy And Surgical Procedures									[rms_v1.0].[Biopsy/Surgical Procedures] skos:exactMatch [rms_v2.0].[Biopsy And Surgical Procedures]	
TG	One record per subject per surgical procedure										
VD	HONEST_BROKER_SUBJECT_ID	String		The identifier assigned to the subject by the honest broker. An individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a "re-identification code"), however the information linking this re- identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.	ncit:C168949	_undefined_	_undefined_	_undefined_		New VD	
VD	AGE_AT_PROCEDURE	Integer		Age of subject (in days) at procedure.		_undefined_	_undefined_	_undefined_			
VD	TIME_PERIOD_SUBMITTER_ID	String		This is the SUBMITTER_ID of the time period (defined in the "Time Period" table) during which this observation takes place.		_undefined_	_undefined_	_undefined_		New VD	
VD	CLASSIFICATION	Enum		The classification of a tumor based primarily on histopathological characteristics.		_undefined_	_undefined_	_undefined_		[rms_v1.0].[Biopsy/Surgical Procedures].[TUMOR_CLASSIFICATION] skos:exactMatch [rms_v2.0].[Biopsy And Surgical Procedures].[CLASSIFICATION]	
PD						Primary	A tumor at the original site of origin.	C8509			
PD						Regional			Changed from "Regional Nodes" to "Regional" BTF 20210801		
PD						Metastatic	A tumor that has spread from its original (primary) site of growth to another site, close to or distant from the primary site. Metastasis is characteristic of advanced malignancies, but in rare instances can be seen in neoplasms lacking malignant morphology.	C3261			
PD						Unknown	Reported as unknown by the data contributor.	C17998			
PD						Not Reported	Not provided or available.	C43234			
VD	SITE	Enum		The anatomical site on which surgery was performed.		_undefined_	_undefined_	_undefined_		[rms_v1.0].[Biopsy/Surgical Procedures].[PROCEDURE_SITE] skos:exactMatch [rms_v2.0].[Biopsy And Surgical Procedures].[SITE]	
PD						Abdomen					
PD						Anal/Perianal					
PD						Bladder					
PD						Bladder/Prostate					
PD						Bone					
PD						Bone Marrow					
PD						Bone or Bone Marrow					
PD						Brain					
PD						Cervix					
PD						Cheek					
PD						Distant Lymph Nodes					
PD						Eyelid					
PD						Foot					
PD						Forearm					
PD						Hand					
PD						Hypopharynx					
PD						Infratemporal Fossa/Pterygopalatine					
PD						Infratemporal Fossa/Pterygopalatine and Parapharyngeal Area					
PD						Kidney					
PD						Knee					
PD						Larynx					
PD						Leg					
PD						Liver/Biliary Tract					
PD						Lower Leg					
PD						Lung					
PD						Middle Ear					
PD						Nasal Cavity					
PD						Nasal Cavity and Paranasal Sinuses					
PD						Nasopharynx					
PD						Neck					
PD						Oral Cavity					
PD						Orbit					
PD						Oropharynx					
PD						Ovary					
PD						Paranasal Sinuses					
PD						Parapharyngeal Area					
PD						Paraspinal					
PD						Paratesticular					
PD						Parotid					
PD						Pelvis					
PD						Perineum					
PD						Pleural Effusion					
PD						Prostate					
PD						Retroperitoneum					
PD						Scalp					
PD						Shoulder					
PD						Soft Tissue					
PD						Thigh					
PD						Thorax					
PD						Thyroid and Parathyroid					
PD						Trunk					
PD						Upper Arm					
PD						Uterus					
PD						Vagina					
PD						Vulva					
PD						Other					
PD						Unknown					
PD						Not Reported					
VD	PROCEDURE_TYPE	Enum		A categorization of surgical procedures by type or purpose.		_undefined_	_undefined_	_undefined_			
PD						Surgery	A diagnostic or treatment procedure performed by manual and/or instrumental means, often involving an incision and the removal or replacement of a diseased organ or tissue; of or relating to or involving or used in surgery or requiring or amenable to treatment by surgery.	C15329			
PD						Biopsy	The removal of tissue specimens or fluid from the living body for microscopic examination, performed to establish a diagnosis.	C15189			
VD	MARGINS	Enum		One of the criteria for assessment of the effectiveness of given surgical procedure in achieving the local control of a neoplasm and the adequacy of tumor removal. It is defined by the tissue plane through which the dissection has been done and the actual or potential neoplastic tissue which has been left outside the boundary of a resected specimen within the patient. There are four types of surgical margins: intracapsular or intralesional, marginal, wide, and radical.		_undefined_	_undefined_	_undefined_			
PD						Incomplete Resection					
PD						R0 - Complete Resection, Negative	No detectable presence of residual tumor after treatment	C139578			
PD						R1 - Complete Resection, Positive	Presence of microscopic residual tumor after treatment.	C139579			
PD						R2 - Gross Residual Disease	Presence of macroscopic residual tumor after treatment.	C139580			
PD						Gross Total Resection, Unknown Margins					
PD						Unknown	Reported as unknown by the data contributor.	C17998			
PD						Not Reported	Not provided or available.	C43234			
											
											
DD	Response										
TD	Subject Response										
TG	One row per subject per response assessment per response method										
VD	HONEST_BROKER_SUBJECT_ID	String		The identifier assigned to the subject by the honest broker. An individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a "re-identification code"), however the information linking this re- identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.	ncit:C168949	_undefined_	_undefined_	_undefined_		New VD	
VD	AGE_AT_RESPONSE	Integer		Age of subject (in days) when the response assessment was made.		_undefined_	_undefined_	_undefined_			
VD	TX_PRIOR_RESPONSE	Enum		Treatment Type Prior to Response Assessment		_undefined_	_undefined_	_undefined_			
PD						Chemotherapy					
PD						Chemoradiotherapy					
VD	RESPONSE	Enum		The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.		_undefined_	_undefined_	_undefined_			
PD						Partial Response					
PD						Stable Disease					
PD						Progressive Disease					
PD						Complete Response					
PD						Not Evaluable					
											
											
DD	Events										
TD	Subsequent Malignant Neoplasm									[rms_v1.0].[Secondary Malignant Neoplasm] skos:exactMatch [rms_v2.0].[Subsequent Malignant Neoplasm]	
TG	One row per subject per subsequent malignancy										
VD	AGE_AT_SMN	Integer		Age in Days at Subsequent Malignant Neoplasm	C168860	_undefined_	_undefined_	_undefined_			